Operating expenses, including selling, general and administrative (SG&A), research and development (R&D) and restructuring and acquisition integration charges totaled $319 million, or 38 percent of total revenue. Excluding $11 million of nonrecurring items, adjusted operating expenses totaled $308 million, or 36 percent of total revenue. Adjusted SG&A expenses were $269 million and R&D investments totaled $39 million.
New Reporting SegmentsIn July 2011, the company realigned its businesses under two new global operating segments named Medical Systems and Procedural Solutions. Beginning with the first quarter of fiscal 2012, the company also made a determination to realign its reportable segments with the new operating segments. Accordingly, the company is reporting results under these two segments, which are replacing the Critical Care Technologies and Medical Technologies and Services segments under which the company had previously reported. The Medical Systems segment includes the company's Dispensing Technologies, Infusion Systems and Respiratory Technologies business lines. The Procedural Solutions segment includes the company's Infection Prevention, Medical Specialties and Specialty Disposables business lines. The company has separately provided summary historical financial data for the new reportable segments in a report on Form 8-K filed with the Securities and Exchange Commission on Nov. 2, 2011.
Medical SystemsRevenue for the Medical Systems segment increased 9 percent on a reported basis to $509 million, or 7 percent on a constant currency basis, driven by Dispensing Technologies and Infusion Systems sales. Sales in the company's Dispensing Technologies
Copyright©2010 PR Newswire.
All rights reserved